Evidence map›Paper›PMID 32872092›Full record

ArticleMedicina (Kaunas, Lithuania)2020

Significance of acPWV for Survival of Hemodialysis Patients.

Marko Petrovic, Marko Baralic, Voin Brkovic, Aleksandra Arsenovic, Vesna Stojanov, Natasa Lalic, Dejana Stanisavljevic, Aleksandar Jankovic, Nenad Radivojevic, Svetlana Pejanovic and 2 more

Open access · goldAbstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Marko PetrovicClinical Centre of Serbia, Department of Nephrology, 11000 Belgrade, Serbia.
Marko BaralicClinical Centre of Serbia, Department of Nephrology, 11000 Belgrade, Serbia.ORCID 0000-0001-5585-9793
Voin BrkovicClinical Centre of Serbia, Department of Nephrology, 11000 Belgrade, Serbia.
Aleksandra ArsenovicSpecial Hospital for Endemic Nephropathy, 11555 Lazarevac, Serbia.
Vesna StojanovSchool of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Natasa LalicClinical Centre of Serbia, Centre for Medical Biochemistry, 11000 Belgrade, Serbia.
Dejana StanisavljevicInstitute for Medical Statistics, School of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Aleksandar JankovicClinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.
Nenad RadivojevicClinical Centre of Serbia, Department of Cardiology, 11000 Belgrade, Serbia.
Svetlana PejanovicClinical Centre of Serbia, Department of Nephrology, 11000 Belgrade, Serbia.
Ivko MaricSpecial Hospital for Endemic Nephropathy, 11555 Lazarevac, Serbia.
Visnja LezaicClinical Centre of Serbia, Department of Nephrology, 11000 Belgrade, Serbia.
University of Belgrade · RSKliničko Bolnički Centar Zvezdara · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAbnormal arterial stiffness (AS) is a major complication in end-stage kidney disease (ESKD) patients treated by dialysis. Our study aimed to determine the significance of AS for survival of prevalent dialysis patients, as well as its association with cardiovascular parameters or vascular calcification promoters/inhibitors or both and AS. MATERIALS AND

methodsThe study involved 80 adult hemodialysis patients. Besides standard laboratory analyses, we also determined promoters and inhibitors of vascular calcification (bone biomarkers): serum levels of fibroblast growth factor 23 (FGF23), soluble Klotho, intact parathormone (iPTH), 1,25-dihydroxyvitamin D3, osteoprotegerin, sclerostin, AS measured as ankle carotid pulse wave velocity (acPWV), Ankle Brachial Index (ABI), and vascular calcification (VC) score. Patients were monitored for up to 28 months. According to the median acPWV value, we divided patients into a group with acPWV ≤ 8.8 m/s, and a group with acPWV > 8.8 m/s, and the two groups were compared.

resultsValues for bone biomarkers were similar in both groups. Mean arterial blood pressure (MAP), central systolic and diastolic brachial blood pressure, heart rate, and pulse pressure were higher in the group with acPWV > 8.8 m/s than in the group with acPWV ≤ 8.8 m/s. The mortality was higher for patients with acPWV > 8.8 m/s at any given time over 28 months of follow-up. In multivariable analysis, predictors of higher acPWV were age >60.5, higher pulse rate, and higher central systolic or brachial diastolic blood pressure.

conclusionsAccording to our results, we advise the measurement of acPWV preferentially in younger dialysis patients for prognosis, as well as intervention planning before the development of irreversible changes in blood vessels. In addition, measuring central systolic blood pressure seems to be useful for monitoring AS in prevalent hemodialysis patients.

Indexed as

Cardio Ankle Vascular IndexRenal DialysisAgedAnkle Brachial IndexBiomarkersCause of DeathFemaleFibroblast Growth Factor-23Heart RateHumansKidney Failure, ChronicMaleMiddle AgedSurvival AnalysisVascular CalcificationVascular StiffnessBiomarkersFGF23 protein, humanFibroblast Growth Factor-23arterial stiffnessbiomarkerscardiovascular assessmentoutcomeprevalent hemodialysis patients

Identifiers

PMID32872092
PMCPMC7558400
OpenAlexW3080978924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.